In vivo use of OKT3: main issues for the monitoring of treated patients.
Chatenoud
L
L
INSERM U 25, Hôpital Necker, Paris, France.
Ferran
C
C
Bach
J F
JF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis; D006801:Humans; D007165:Immunosuppression Therapy; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D015166:Monitoring, Immunologic; D016853:Muromonab-CD3; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D016853:Muromonab-CD3